This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Apricus Biosciences, Inc.
Drug Names(s): alprostadil cream, transdermal alprostadil
Description: Femprox is an alprostadil-based cream for the treatment of FSAD.
Femprox exerts a relaxant effect on vulvar and clitoral blood vessels in women, leading to increased blood flow. This leads to pelvic engorgement and enhanced secretion activity of the vulvar epithelium. The resultant increase in lubrication and sensory feedback due to pelvic engorgement is believed to produce a clinically significant increase in sexual arousal in women with FSAD. Femprox enables a rapid permeation of blood deep into the target tissues thus enabling a new pharmacotherapy for the treatment of FSAD through increasing the blood flow to tissue.
Additional information available to subscribers only: